Aprea Therapeutics, Inc. (APRE)
NCM · Healthcare · Biotechnology
$0.77
-1.91%
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
Market Cap
$9.7M
Shares Outstanding
12.6M
Exchange
NCM
Currency
USD
About Aprea Therapeutics, Inc.
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (3.1M) | (2.6M) | (3.4M) | (4.0M) |
| Net Income | (3.0M) | (2.5M) | (3.3M) | (3.6M) |
| Diluted EPS | $-0.47 | $-0.32 | $-0.22 | $-0.07 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (37.4M) | (15.5M) | (14.3M) | (13.2M) |
| Net Income | (112.7M) | (14.3M) | (13.0M) | (12.6M) |
| Diluted EPS | $-67.99 | $-3.95 | $-2.35 | $-1.93 |